Efficiency of venlafaxine in patients with psychogenic nonepileptic seizures and anxiety and/or depressive disorders.
Pintor
Luis
L
Psychiatry Department, Neuroscience Institute, Hospital Clínico de Barcelona, Barcelona, Spain. lpintor@clinic.ub.es
Baillés
Eva
E
Matrai
Silvia
S
Carreño
Mar
M
Donaire
Antonio
A
Boget
Teresa
T
Setoain
Xavier
X
Rumia
Jordi
J
Bargalló
Nuria
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy*; D003511:Cyclohexanols / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D004569:Electroencephalography / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012640:Seizures / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D018709:Statistics, Nonparametric; D000069470:Venlafaxine Hydrochloride; D014741:Video Recording / Q000379:methods; D055815:Young Adult
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride